Abstract
Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Current Molecular Medicine
Title: From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Volume: 3 Issue: 5
Author(s): E. A. Thomas, D. L. Copolov and J. G. Sutcliffe
Affiliation:
Keywords: pharmacotherapy, pathophysiology, apolipoprotein d, psychiatric disorders, lipocalin protein superfamily
Abstract: Apolipoprotein D (apoD) is an atypical plasma apolipoprotein and, based on its primary structure, it is a member of the lipocalin protein superfamily. Lipocalins have been extensively used as disease markers and, accordingly, apoD has become increasingly recognized as an important factor in the pathology of human neurodegenerative and neuropsychiatric disorders. ApoD expression is increased in the plasma and brains of subjects with schizophrenia and bipolar disorder, suggesting that it acts as a marker for disease pathology. ApoD also exhibits complex regulation by antipsychotic drug treatment and may represent a distinguishing mechanism of typical versus atypical drugs. The precise role of apoD in the CNS and disease remains to be elucidated, but recent findings have suggested that it plays an important role in the regulation of arachidonic acid signaling and metabolism providing further support for phospholipid membrane pathology in schizophrenia.
Export Options
About this article
Cite this article as:
Thomas A. E., Copolov L. D. and Sutcliffe G. J., From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders, Current Molecular Medicine 2003; 3 (5) . https://dx.doi.org/10.2174/1566524033479681
DOI https://dx.doi.org/10.2174/1566524033479681 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Current Medicinal Chemistry An Up-to-Date Review on Citrus Flavonoids: Chemistry and Benefits in Health and Diseases
Current Pharmaceutical Design Assessment of the Effect of Macromolecular Crowding on Aggregation Behaviour of a Model Amyloidogenic Peptide
Protein & Peptide Letters Editorial (Thematic Issue: New Insight into Lipid Disorders)
Current Medicinal Chemistry Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Mechanisms of Oxidative Glutamate Toxicity: The Glutamate/Cystine Antiporter System xc¯ as a Neuroprotective Drug Target
CNS & Neurological Disorders - Drug Targets Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry Editorial
Current Molecular Medicine Limb-girdle Muscular Dystrophy and Therapy: Insights into Cell and Gene-based Approaches
Current Gene Therapy γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Current Pharmaceutical Design The Immune Protective Effect of the Mediterranean Diet against Chronic Low-grade Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of the Adamantane Structure in Medicinal Chemistry
Current Medicinal Chemistry Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Calcium-Sensing Receptors of Human Astrocyte-Neuron Teams: Amyloid-β-Driven Mediators and Therapeutic Targets of Alzheimer's Disease
Current Neuropharmacology Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets